- Home
- ZLAB
ZLAB
Zai Lab Limited
as 03-28-2025 4:00pm EST
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | N/A | IPO Year: | 2017 |
| Target Price: | $47.37 | AVG Volume (30 days): | 900.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.48 - $39.77 | Next Earning Date: | 05-07-2025 |
| Revenue: | $398,988,000 | Revenue Growth: | 49.59% |
| Revenue Growth (this year): | 45.57% | Revenue Growth (next year): | 47.91% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Amado Rafael | ZLAB | See Remarks | Mar 17 '25 | Sell | $38.41 | 3,000 | $115,230.00 | 30,834 | |
| GAYNOR RICHARD | ZLAB | Director | Mar 5 '25 | Sell | $35.07 | 2,500 | $87,675.00 | 44,068 | |
| Du Ying | ZLAB | Chairperson & CEO | Mar 4 '25 | Sell | $34.25 | 96,389 | $3,323,324.25 | 494,117 | |
| Du Ying | ZLAB | Chairperson & CEO | Feb 28 '25 | Sell | $33.57 | 100,000 | $3,345,606.67 | 494,117 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Feb 28 '25 | Sell | $32.98 | 14,544 | $479,661.12 | 14,328 | |
| Lis William | ZLAB | Director | Feb 28 '25 | Sell | $32.98 | 15,000 | $494,700.00 | 38,089 | |
| Chen Kai-Xian | ZLAB | Director | Dec 31 '24 | Sell | $17.22 | 7,750 | $133,455.00 | 60,778 | |
| Amado Rafael | ZLAB | See Remarks | Dec 30 '24 | Sell | $26.28 | 7,583 | $199,288.82 | 30,834 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
Insider Monkey
15 days ago
Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?
TipRanks
15 days ago
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
MT Newswires
16 days ago
JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating
MT Newswires
16 days ago
Zai Lab's Tivdak Marketing Application Accepted in China for Cervical Cancer Treatment
Business Wire
16 days ago
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zacks
25 days ago
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
MT Newswires
25 days ago
Zai Lab Shares Fall After BofA Securities Downgrade
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.